Response to Huang et al, “Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the CRDC”
Response to Huang et al, “Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the CRDC”. // Journal of the American Academy of Dermatology. – URL: https://www.sciencedirect.com/science/article/pii/S0190962226030197?dgcid=rss_sd_all
Response to Huang et al, “Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the CRDC”. Journal of the American Academy of Dermatology. https://www.sciencedirect.com/science/article/pii/S0190962226030197?dgcid=rss_sd_all
“Response to Huang et al, “Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the CRDC”.” Journal of the American Academy of Dermatology.
@article{article89966,
title = {Response to Huang et al, “Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the CRDC”},
journal = {Journal of the American Academy of Dermatology},
url = {https://www.sciencedirect.com/science/article/pii/S0190962226030197?dgcid=rss_sd_all}
}